Loading clinical trials...
Loading clinical trials...
NanO2 in Large VessEL Occlusion Stroke (NOVEL): a Multicentre Single-blind, Randomised, Placebo-controlled Blinded Biomarker End-point Clinical Trial of Perfluorocarbon in Acute Ischaemic Stroke Due to Large Vessel Occlusion
Conditions
Interventions
NanO2TM
Sodium Chloride 0.9% Intravenous
Locations
1
United Kingdom
NHS Greater Glasgow and Clyde
Glasgow, United Kingdom, United Kingdom
Start Date
May 1, 2025
Primary Completion Date
July 31, 2026
Completion Date
July 31, 2026
Last Updated
April 4, 2025
NCT07052045
NCT07001852
NCT07080567
NCT06727006
NCT06315192
NCT06967025
Lead Sponsor
NHS Greater Glasgow and Clyde
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions